Singh SR, Fung AT, Fraser-Bell S, et al. - In eyes with peripapillary choroidal neovascularisation (CNV) through 12 months, researchers reported the visual and anatomical outcomes. This was a multicentre, retrospective, interventional case series that involved peripapillary choroidal neovascular membrane (CNVM) treatment-naïve cases with a minimum 12-month follow-up. The study sample consisted of 77 eyes (74 patients; mean age: 61.9±21.8 years) with a mean disease duration of 9.2 ± 14.1 months. Investigators found that best corrected visual acuity (BCVA) significantly improved from 0.55 ± 0.54 logMAR (20/70) at baseline to 0.29 ± 0.39 logMAR (20/40) at 12 months with a mean of 4.9 ± 2.9 anti-vascular endothelial growth factors (VEGF) injections. At the CNVM site, CMT, SFCT and retinal thickness decreased significantly over 12 months. Neovascular age-related macular degeneration, and idiopathic, inflammatory and angioid streaks were the most common disease aetiologies were. At 12 months, age and baseline BCVA were significant predictors of change in BCVA. Although unusual, peripapillary CNVM is connected with various aetiologies. Anti-VEGF agents in these eyes lead to significant visual acuity and long-term anatomical improvement, regardless of aetiology.